Association of α-, β-, and γ-synuclein with diffuse lewy body disease

Archives of Neurology

Volumn 67, Issue 8, 2010, Pages 970-975

  Nishioka, Kenya ^a   Wider, Christian ^a   Vilariño Güell, Carles ^a   Soto Ortolaza, Alexandra I ^a   Lincoln, Sarah J ^a   Kachergus, Jennifer M ^a   Jasinska Myga, Barbara ^a,b   Ross, Owen A ^a   Rajput, Alex ^c   Robinson, Christopher A ^c   Ferman, Tanis J ^a   Wszolek, Zbigniew K ^a   Dickson, Dennis W ^a   Farrer, Matthew J ^a  

^a MAYO CLINIC   (United States)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c ROYAL UNIVERSITY HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; BETA SYNUCLEIN; GAMMA SYNUCLEIN;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DEMENTIA; DIFFUSE LEWY BODY DISEASE; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PHYLOGENY; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ANIMALS; BETA-SYNUCLEIN; EVOLUTION; FEMALE; GAMMA-SYNUCLEIN; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; LEWY BODY DISEASE; LINKAGE DISEQUILIBRIUM; MALE; PHYLOGENY; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77955447233     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2010.177     Document Type: Article

References (41)

1. Kosaka K. Diffuse Lewy body disease. Intern Med. 1998;37(1):6-10.
2. McKeith IG, Dickson DW, Lowe J, et al; Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology. 2005;65(12):1863-1872.
3. Fujishiro H, Ferman TJ, Boeve BF, et al. Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases. J Neuropathol Exp Neurol. 2008;67(7):649-656.
4. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology. 2001;57(8):1497-1499.
5. Dickson DW, Liu W, Hardy J, et al. Widespread alterations of alpha-synuclein in multiple system atrophy. Am J Pathol. 1999;155(4):1241-1251.
6. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839-840.
7. Farrer MJ. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet. 2006;7(4):306-318.
8. Scholz SW, Houlden H, Schulte C, et al. SNCA variants are associated with increased risk for multiple system atrophy [published correction appears in Ann Neurol. 2010;67(2):277]. Ann Neurol. 2009;65(5):610-614.
9. Ross OA, Vilariño-Güell C, Zbigniew WK, Farrer MJ, Dickson DW. Reply to: SNCA variants are associated with increased risk of multiple system atrophy. Ann Neurol. 2009;67(3):414-415.
10. George JM. The synucleins [published online ahead of print December 20, 2001]. Genome Biol. 2002;3(1):REVIEWS3002.
11. Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science. 2000;287(5456):1265-1269.
12. Hashimoto M, Rockenstein E, Mante M, Mallory M, Masliah E. beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron. 2001;32(2):213-223. (Pubitemid 33030190)
13. Fan Y, Limprasert P, Murray IV, et al. Beta-synuclein modulates alpha-synuclein neurotoxicity by reducing alpha-synuclein protein expression. Hum Mol Genet. 2006;15(20):3002-3011.
14. Ohtake H, Limprasert P, Fan Y, et al. Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology. 2004;63(5):805-811.
15. Galvin JE, Uryu K, Lee VM, Trojanowski JQ. Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc Natl Acad Sci U S A. 1999;96(23):13450-13455.
16. Ninkina N, Peters O, Millership S, Salem H, van der Putten H, Buchman VL. Gamma-synucleinopathy: neurodegeneration associated with overexpression of the mouse protein [published online February 26, 2009]. Hum Mol Genet. 2009;18(10):1779-1794.
17. Kosaka K. Diffuse Lewy body disease in Japan. J Neurol. 1990;237(3):197-204. (Pubitemid 20209309)
18. Kosaka K, Tsuchiya K, Yoshimura M. Lewy body disease with and without dementia: a clinicopathological study of 35 cases. Clin Neuropathol. 1988;7(6):299-305. (Pubitemid 19019180)
19. Kosaka K, Yoshimura M, Ikeda K, Budka H. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree: a new disease? Clin Neuropathol. 1984;3(5):185-192.
20. Barker WW, Luis CA, Kashuba A, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord. 2002;16(4):203-212.
21. Uchikado H, Lin WL, DeLucia MW, Dickson DW. Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol. 2006;65(7):685-697. (Pubitemid 44297259)
22. Mata IF, Kachergus JM, Taylor JP, et al. Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics. 2005;6(4):171-177.
23. Siepel A, Bejerano G, Pedersen JS, et al. Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res. 2005;15(8):1034-1050.
24. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet. 2004;74(4):765-769.
25. Flowers JM, Leigh PN, Davies AM, et al. Mutations in the gene encoding human persyn are not associated with amyotrophic lateral sclerosis or familial Parkinson's disease. Neurosci Lett. 1999;274(1):21-24.
26. Krüger R, Schöls L, Müller T, et al. Evaluation of the gamma-synuclein gene in German Parkinson's disease patients. Neurosci Lett. 2001;310(2-3):191-193. (Pubitemid 32822835)
27. Leimeister C, Steidl C, Schumacher N, Erhard S, Gessler M. Developmental expression and biochemical characterization of Emu family members. Dev Biol. 2002;249(2):204-218.
28. Mizuta I, Satake W, Nakabayashi Y, et al. Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease. Hum Mol Genet. 2006;15(7):1151-1158.
29. Mueller JC, Fuchs J, Hofer A, et al. Multiple regions of alpha-synuclein are associated with Parkinson's disease. Ann Neurol. 2005;57(4):535-541.
30. Winkler S, Hagenah J, Lincoln S, et al. alpha-Synuclein and Parkinson disease susceptibility. Neurology. 2007;69(18):1745-1750.
31. Pals P, Lincoln S, Manning J, et al. alpha-Synuclein promoter confers susceptibility to Parkinson's disease. Ann Neurol. 2004;56(4):591-595.
32. Fung HC, Scholz S, Matarin M, et al. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol. 2006;5(11):911-916. (Pubitemid 44556544)
33. Brighina L, Okubadejo NU, Schneider NK, et al. Beta-synuclein gene variants and Parkinson's disease: a preliminary case-control study. Neurosci Lett. 2007;420(3):229-234. (Pubitemid 46856017)
34. Lavedan C, Buchholtz S, Auburger G, et al. Absence of mutation in the beta- and gamma-synuclein genes in familial autosomal dominant Parkinson's disease. DNA Res. 1998;5(6):401-402.
35. Lincoln S, Crook R, Chartier-Harlin MC, et al. No pathogenic mutations in the beta-synuclein gene in Parkinson's disease. Neurosci Lett. 1999;269(2):107-109. (Pubitemid 29335424)
36. Tárraga J, Medina I, Arbiza L, et al. Phylemon: a suite of web tools for molecular evolution, phylogenetics and phylogenomics [published online ahead of print April 22, 2007]. Nucleic Acids Res. 2007;35(Web server issue):W38-W42.
37. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997;276(5321):2045-2047.
38. Krüger R, Kuhn W, Müller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet. 1998;18(2):106-108.
39. Zarranz JJ, Alegre J, Gomez-Esteban JC, et al. The new mutation, E46K, of alphasynuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004;55(2):164-173. (Pubitemid 38166992)
40. Park JY, Lansbury PT Jr. Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease. Biochemistry. 2003;42(13):3696-3700.
41. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837-844.